Vipadenant

Drug Profile

Vipadenant

Alternative Names: BG-14; BIIB-014; BIIB14; CEB-4520; V2006; VER-11135; VER-A00-11; VER-A00049; VER-ADO-49; VR-2006

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Vernalis
  • Developer Biogen Idec; Juno Therapeutics
  • Class Antiparkinsonians; Pyrimidines; Small molecules; Triazoles
  • Mechanism of Action Adenosine A2 receptor antagonists; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer
  • Discontinued Parkinson's disease

Most Recent Events

  • 14 Jul 2016 RedoxTherapies has been acquired by Juno Therapeutics
  • 09 Oct 2014 Vernalis grants exclusive worldwide license to RedoxTherapies for vipadenant for use in immuno-oncology
  • 09 Oct 2014 Preclinical trials in Cancer (Combination therapy) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top